Vis enkel innførsel

dc.contributor.authorFarup, Per Grønaas
dc.contributor.authorMaseng, Maria G.
dc.date.accessioned2021-09-24T06:32:18Z
dc.date.available2021-09-24T06:32:18Z
dc.date.created2021-04-13T14:03:43Z
dc.date.issued2021
dc.identifier.citationMicroorganisms. 2021, 9 (3), .en_US
dc.identifier.issn2076-2607
dc.identifier.urihttps://hdl.handle.net/11250/2781247
dc.description.abstractBackground: An abnormal faecal microbiota could be a causal factor for disease. This study evaluated a new method for faecal microbiota analysis in subjects with obesity and irritable bowel syndrome. Methods: The study had a matched case-control design. Forty-six subjects with morbid obesity (defined as BMI > 40 or >35 kg/m2 with obesity-related complications) of whom 23 had irritable bowel syndrome (IBS), were compared with 46 healthy volunteers. The faecal microbiota was analysed with Precision Microbiome Profiling (PMP™) which quantified 104 bacteria species. The primary aim was comparisons between the cases and controls. Results: Two men and 44 women with a mean age of 43.6 years were included in each of the groups; BMI in the groups was (mean and SD) 41.9 (3.5) and 22.5 (1.5) kg/m2, respectively. Seventeen bacterial species showed statistically significant differences between the groups after adjusting for multiple testing. In a post hoc analysis, the sensitivity and specificity were 78%. Alpha diversity was lower in the group with obesity. In subjects with morbid obesity, no clinically significant differences were seen between subjects with and without IBS or from before to six months after bariatric surgery. Conclusions: The results encourage further evaluation of the new microbiome profiling tool. Keywords: faecal microbiota; obesity; irritable bowel syndrome; biomarker; shotgun analyses; the HUNT studyen_US
dc.language.isoengen_US
dc.publisherMDPIen_US
dc.relation.urihttps://www.mdpi.com/2076-2607/9/3/664/htm
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleAre faecal microbiota analyses on species-level suitable clinical biomarkers? A pilot study in subjects with morbid obesityen_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.description.versionpublishedVersionen_US
dc.source.pagenumber11en_US
dc.source.volume9en_US
dc.source.journalMicroorganismsen_US
dc.source.issue3en_US
dc.identifier.doi10.3390/microorganisms9030664
dc.identifier.cristin1903815
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal